Resetting the Immune System to Drive Long-Term Disease Remission in Autoimmune and Allergic Diseases with Jonathan Rigby Revolo Biotherapeutics

Published: April 6, 2021, 4:43 p.m.

Jonathan Rigby, CEO, Revolo Biotherapeutics discusses the company's revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, with less frequent chronic dosing and without suppression of the immune system. A goal that others have not been able to reach. Revolo Bio's platform drug candidates '1805 and '1104 are in development for rheumatoid arthritis, uveitis, eosinophilic esophagitis and allergic diseases.

@RevoloBio #AutoimmuneDisease #AllergicDisease #RheumatoidArthritis #Uveitis #EosinophilicEsophagitis

RevoloBio.com

Download the transcript here